Patent EP0136835A2 successfully refreshed from Google Patents.
EP0136835A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Process for the preparation of antibody compositions of therapeutic agents having an extended serum half-life
Assignee: Hybritech Inc
•
Filing: 1984-09-03
•
Granted: —
•
Expires: 2004-09-03
Abstract
Abstract A therapeutic agent e.g. alpha-interferon, complexes with an antibody without impairing the activity. The antibody can be a monoclonal antibody. The serum half-life of the therapeutic agent administered as the complex is substantially increased when compared to that of the agent administered alone.
Inventors
- 👤 James M. Frincke
- 👤 Barbara W. Unger
- 👤 Karen G. Burnett
- 👤 Evan Myron Hersh
- 👤 Michael Gordon Rosenblum
- 👤 Jordan Udell Gutterman
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-02 13:59
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/46; C07K16/468; A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/21; A61K39/00; A61K39/395; A61K47/00; A61K47/50; A61K47/51; A61K47/68; A61K47/6835; A61K47/6875; A61K47/6879
Claims Analysis
Total Claims: 33
Claim 1
Independent Claim
40 words
A composition comprising a complex of a therapeutically active agent and an antibody selected to bind said agent at a site which does not substantially impair its therapeutic activity and which extends the serum half-life of the therapeutically active agent.
Claim 2
Dependent Claim
40 words
A composition comprising a complex of a therapeutically active agent and an antibody selected to bind said agent at a site which does not substantially impair its therapeutic activity and which extends the serum half-life of the therapeutically active agent.
Claim 3
Dependent Claim
13 words
A composition according to claim 1 wherein the antibody is a monoclonal antibody.
Claim 4
Dependent Claim
15 words
A composition according to claim 1 wherein the antibody comprises a population of polyclonal antibodies.
Claim 5
Dependent Claim
35 words
A composition according to claim 1 wherein the antibody is a hybrid monoclonal antibody having a dual specificity one of which is against the therapeutically active agent and the other against a disease associated antigen.
Claim 6
Dependent Claim
29 words
A composition according to claim 4 wherein one specificity of the hybrid antibody is directed against a tumour associated antigen and the other against an agent having anti-tumour activity.
Claim 7
Dependent Claim
17 words
A composition according to claim 5 wherein the tumour associated antigen is CEA, PAP, PSA or ferritin.
Claim 8
Dependent Claim
17 words
A composition according to claim 5 or 6 wherein the second specificity is directed against an interferon.
Claim 9
Dependent Claim
23 words
A composition according to any one of the preceding claims wherein the antibody comprises an antibody fragment which is Fab, Fab' or Fab'2.
Claim 10
Dependent Claim
22 words
A composition according to any one of the preceding claims, wherein the therapeutically active agent is a drug, toxin or biological protein.
Claim 11
Dependent Claim
18 words
A composition according to any one of the preceding claims wherein the therapeutically active agent is an interferon.
Claim 12
Dependent Claim
16 words
ll. A composition according to claim 10 wherein the interferon is alpha, beta or gamma interferon.
Claim 13
Dependent Claim
15 words
A composition according to any one of the preceding claims further comprising a pharmaceutical vehicle.
Claim 14
Dependent Claim
39 words
A composition according to any one of the preceding claims for use in a process for treatment of the human or animal body by surgery or therapy or in a diagnostic method practised on the human or animal body.
Claim 15
Dependent Claim
21 words
A composition according to claim 13 wherein the process is one in which the antibody and agent are combined in vitro.
Claim 16
Dependent Claim
26 words
A composition according to claim 13 wherein the process is one in which the antibody and agent are separately administered to the human or animal body.
Claim 17
Dependent Claim
32 words
A composition according to claim 15 wherein the process is one in which the antibody is allowed to distribute itself throughout the human or animal body prior to administration of the agent.
Claim 18
Dependent Claim
52 words
A process for the production of a complex of a therapeutically active agent and an antibody selected to bind said agent at a site which does not substantially impair its therapeutic activity and which extends the serum half-life of the therapeutically active agent which comprises combining the antibody and agent in vitro.
Claim 19
Dependent Claim
52 words
A process for the production of a complex of a therapeutically active agent and an antibody selected to bind said agent at a site which does not substantially impair its therapeutic activity and which extends the serum half-life of the therapeutically active agent which comprises combining the antibody and agent in vitro.
Claim 20
Dependent Claim
55 words
A process for the production of a complex of a therapeutically active agent and an antibody selected to bind said agent at a site which does not substantially impair its therapeutic activity and which extends the serum half-life of the therapeutically active agent which comprises combining the antibody and agent in a host in vivo.
Claim 21
Dependent Claim
55 words
A process for the production of a complex of a therapeutically active agent and an antibody selected to bind said agent at a site which does not substantially impair its therapeutic activity and which extends the serum half-life of the therapeutically active agent which comprises combining the antibody and agent in a host in vivo.
Claim 22
Dependent Claim
21 words
A process according to claim 2 wherein the antibody is distributed throughout the host prior to the introduction of the agent.
Claim 23
Dependent Claim
17 words
A process according to any one of the preceding claims wherein the antibody is a monoclonal antibody.
Claim 24
Dependent Claim
20 words
A process according to any one of claims 1 to 3 wherein the antibody comprises a population of polyclonal antibodies.
Claim 25
Dependent Claim
40 words
A process according to any one of claims 1 to 3 wherein the antibody is a hybrid monoclonal antibody having a dual specificity one of which is against the therapeutically active agent and the other against a disease associated antigen.
Claim 26
Dependent Claim
29 words
A process according to claim 6 wherein one specificity of the hybrid antibody is directed against a tumour associated antigen and the other against an agent having anti-tumour activity.
Claim 27
Dependent Claim
17 words
A process according to claim 7 wherein the tumour associated antigen is CEA, PAP, PSA or ferritin.
Claim 28
Dependent Claim
17 words
A process according to claim 7 or 8 wherein the second specificity is directed against an interferon.
Claim 29
Dependent Claim
23 words
A process according to any one of the preceding claims wherein the antibody comprises an antibody fragment which is Fab, Fab' or Fab'2.
Claim 30
Dependent Claim
22 words
A process according to any one of the preceding claims wherein the therapeutically active agent is a drug, toxin or biological protein.
Claim 31
Dependent Claim
18 words
A process according to any one of the preceding claims wherein the therapeutically active agent is an interferon.
Claim 32
Dependent Claim
15 words
A process according to claim 12 wherein the interferon is alpha, beta or gamma interferon.
Claim 33
Dependent Claim
15 words
A process according to any one of the preceding claims further comprising a pharmaceutical vehicle.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.